KDR Biotech markets DASGIP Parallel Bioreactor Systems in Korea
DASGIP AG and KDR Biotech have signed a cooperation agreement. Thus, KDR Biotech will hold the exclusive distribution of DASGIP Parallel Bioreactor Systems on the Korean market. First sales are already initiated.
Chung, Youn-Taek, Managing Director of KDR Biotech, appreciates the partnership with DASGIP. “By including the DASGIP products into our portfolio we are aiming at winning first class labs in the areas of screening, strain and cell line development as well as process development as new customers”, states Chung, Youn-Taek.
Since 2007 DASGIP has been working on its expansion towards the Asian market. CEO Thomas Drescher points out: “With SCRUM, Tokyo, and Quintech, Singapore, we already are well represented in Japan and Singapore. Now we are happy to have found a reliable partner to enter the Korean market as well”.
Most read news
Organizations
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.